Abiopharma

🔍 Gould Robert J (Executive)

Company: Fulcrum Therapeutics, Inc. (FULC)

Report Date: 2026-01-02

Detailed Transactions and Holdings:

• Sold 15,000 shares of Common Stock at $11.8726 per share (Direct)
  Date: 2026-01-02 | Code: S | equity_swap_involved: false | shares_owned_after: 469,864.00 | transaction_form_type: 4 | Footnotes: F1, F2

Footnotes:

• F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 1, 2025.
• F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.60 to $11.33, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.